Brian Goff - 08 Aug 2023 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: AGIO
Reported as of: 08 Aug 2023
Net transaction value: -$259,335
SEC form: 4
Accepted by SEC: 10 Aug 2023, 16:07:15 UTC
Prior SEC filing: 30 Jun 2023
Next SEC filing: 09 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ William Cook, as Attorney in Fact for Brian Goff

Key filing fact

Brian Goff filed Form 4 for AGIOS PHARMACEUTICALS, INC. (AGIO) on 10 Aug 2023.

Key facts

This page summarizes Brian Goff's Form 4 filing for AGIOS PHARMACEUTICALS, INC. (AGIO).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 10 Aug 2023, 16:07.

Change

Previous filing in this sequence was filed on 30 Jun 2023.
Current net transaction value: -$259,335.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AGIO transaction

Common stock

Options Exercise

Transaction value: $0
Shares: +22,691
Change %: +161%
Price: $0.000000
Shares after: 36,770
Date: 08 Aug 2023
Ownership: Direct

AGIO transaction

Common stock

Sale

Transaction value: $259,335
Shares: -10,178
Change %: -28%
Price: $25.48
Shares after: 26,592
Date: 08 Aug 2023
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AGIO transaction Derivative

Restricted stock units

Options Exercise

Transaction value: $0
Shares: -22,691
Change %: -33%
Price: $0.000000
Shares after: 45,382
Date: 08 Aug 2023
Ownership: Direct
Underlying class: Common stock
Underlying amount: 22,691
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

Footnote F3

The restricted stock units were granted on August 8, 2022. Beginning on August 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments.